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Purpose. To predict the response of cells to chemotherapeutic agents
based on gene expression profiles, we performed a chemoinformatic
study of a set of standard anticancer agents assayed for activity
against a panel of 60 human tumor-derived cell lines from the De-
velopmental Therapeutics Program (DTP) at the National Cancer
Institute (NCI).
Methods. Mechanistically-relevant gene:drug activity associations
were identified in the scientific literature. The correlations between
expression levels of drug target genes and the activity of the drugs
against the NCI’s 60 cell line panel were calculated across and within
each tumor tissue type, using published drug activity and gene ex-
pression data.
Results. Compared to other mechanistically-relevant gene-drug asso-
ciations, that of triciribine phosphate (TCN-P) and adenosine kinase
(ADK) was exceptionally strong—overall and within tumor tissue
types—across the 60 cell lines profiled for chemosensitivity (1) and
gene expression (2).
Conclusion. The results suggest ADK expression may be useful for
stratifying TCN-P-responsive vs. non-responsive tumors. Based on
TCN-P’s mechanism of action and the observed TCN-P:ADK asso-
ciation, we contend that catalytic drug activation provides a rational,
mechanistic basis for personalizing cancer treatment based on tumor-
specific differences in the expression of drug-activating enzymes.
KEY WORDS: triciribine phosphate; adenosine kinase; prodrug;
chemoinformatics; microarray; transcriptional profiling; cancer.
INTRODUCTION
To personalize chemotherapy, anticancer drugs should
be tailored to the phenotypic characteristics of cancer cells.
To study gene:drug activity relationships, the DTP program
has established a database of anticancer agents that have been
screened against a panel of 60 human tumor-derived cell lines
(3–5). To explore gene:drug associations useful for predicting
chemosensitivity (6), genome-wide mRNA expression data
derived from these 60 cell lines (their gene expression pro-
files) have been related to the sensitivity of these cells to a
battery of anticancer agents (their chemosensitivity profiles)
(2,7,8). Correlation analysis yields gene:drug associations that
may be useful for predicting the responsiveness of cancer cells
to anticancer agents.
Previous work (2) found statistically strong predictive
relationships between gene expression and chemosensitivity
for many anticancer agents; however, inspection of the pre-
diction relationship does not provide a clear connection to
drug mechanism of action. There may be many reasons for
this. First, intracellular biochemical pathways are intrinsically
complex and the relationship between drug target inhibition
and cell growth inhibition is complex. In addition, the rela-
tionship between gene transcription, protein levels, and pro-
tein activity may not be directly proportional. Moreover,
many anticancer drugs preferentially target specific tumor tis-
sue types (e.g., leukemia vs. solid tumors), such that coinci-
dental associations between drug activity and tissue-specific
differentiation markers may prevail.
Using public datasets derived from the NCI’s 60 cell line
panel, we report on correlations between gene expression and
chemosensitivity for gene:drug pairs that are known to have a
mechanistic relationship. We considered correlations across
the 60 cell line panel, and within the tumor tissue types rep-
resented in the panel. Out of all possible associations between
anticancer drugs and known targets, that of triciribine phos-
phate (TCN-P) and adenosine kinase (ADK) was exception-
ally strong across and within tumor tissues. This result is con-
sistent with the hypothesis that catalytic drug activation may
provide a rational mechanistic approach to the development
of personalized medicinal chemistry, and suggests that TCN-P
should be reconsidered as a drug for personalized anticancer
therapy.
MATERIALS AND METHODS
Data Sources and Pre-Processing
DNA oligonucleotide measurements derived from the
NCI 60 cell lines covering nine tumor tissues (breast, central
nervous system, colon, leukemia, melanoma, non-small
cell lung cancer, ovary, renal, and prostate) were obtained
from http: / /www.genome.wi .mit .edu/MPR/NC160/
NC160.html. The data were originally analyzed in (2), where
the experimental protocols are described. Measurements
were scaled so that each array had mean expression equal to
1500 U, and the transform log2 (50 + max (X + 50), 0)) was
applied.
Measurements of GI50 (the drug concentration decreas-
ing cell growth by 50%) on the standard anticancer agent
database were obtained from the DTP program website
at the NCI (http://dtp.nci.nih.gov/docs/cancer/searches/
standard_agent_table.html). GI50 values were log2 trans-
formed, and missing values were imputed with the mean over
all cell lines for a given drug.
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Identification of Genes Relevant to Drug Mechanism
of Action
To identify genes relevant to drug mechanism of action,
each drug was used as key word for searching abstracts of
articles in PubMed. In addition, published articles that have
comprehensively explored the relationship between drug
mechanism of action and chemosensitivity profiles of the
standard anticancer agent database were used as references
(2,4–7). Genes and proteins identified as playing a primary
role in drug mechanism of action were matched to specific
genes on the DNA oligonucleotide array, based on gene
name. For example, doxorubicin is a topoisomerase II inhibi-
tor, so expression of the topoisomerase II genes was used
when analyzing doxorubicin. Drugs with unknown mecha-
nism of action—or mechanism of action that does not directly
involve a protein (such as DNA alkylators)—were not con-
sidered.
Statistical Analysis
The Pearson correlation coefficient was used to measure
the relationships between the log-transformed gene expres-
sion and GI50 data, across the 60 cell lines (the “overall cor-
relation”). To isolate within-tumor type associations, correla-
tion coefficients were computed separately for each tissue,
then absolute values of these coefficients were averaged using
weights proportional to the number of samples in a given
tissue.
To assess the significance of the correlation coefficients,
the gene expression levels were randomly permuted 1000 in-
dependent times, over the 60 cell lines. For each permutation,
the correlation with the GI50 levels was recomputed. The
proportion of these correlations that are larger in magnitude
than the actual correlation corresponds to the p value for that
particular gene:drug pair. The distribution of the largest per-
muted correlation among all 364 gene:drug pairs is used to
produce a p value for the largest observed gene:drug corre-
lation.
Results
The concentration at which different anticancer drugs
inhibit cell growth by 50% (the drug’s GI50 concentration)
was graphed relative to the expression level of genes involved
in drug mechanism of action. By visual inspection, it is evident
that cell growth inhibition by TCN-P parallels ADK gene
expression (Fig. 1). The TCN-P:ADK correlation—overall
and within-tissues—was greater than that of the other gene:
drug pairs examined (Supplementary table). Beyond a simple
correlation, the trend covered a substantial magnitude of
variation, in that there is at least an 8-fold spread between the
least and greatest value in ADK gene expression and TCN-P
sensitivity. The correlations within tumor tissue types are also
strong and consistently negative for both copies of ADK,
suggesting that the TCN-P:ADK interaction is specific and
occurs in all tissue types studied.
TCN-P is a water-soluble and plasma membrane-
impermeant, prodrug derivative of triciribine (9). In serum,
TCN-P is de-phosphorylated extracellularly to triciribine
(10), which is then able to traverse the plasma membrane and
inhibit DNA synthesis (11). Nevertheless, TCN-P and tricirib-
ine are inactive unless phosphorylated by intracellular ADK,
at the 5 position (9) (Fig. 2). Intracellular phosphorylation by
ADK is necessary for activation of TCN-P and its parent
compound triciribine. The ADK inhibitor 5-iodotubercidin
decreases the activity of either compound by 200-fold (9).
Also, an ADK-deficient leukemic cell subline is 5000 fold less
sensitive to the drugs than the parent cell line (9,12). More-
over, 5-deoxy derivatives of triciribine are inactive because
they cannot be phosphorylated (13). In HIV-growth inhibi-
Fig. 1. Plot of log2 transform of TCN-P activity (based on the GI50—the drug concentration inhibiting
cell growth by 50%) and adenosine kinase mRNA levels, for each cell line in the NCI’s 60 cell line panel.
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tion assays, phosphorylation of TCN-P by ADK is essential
for antiviral activity (12,13). In fact, these and other related
experiments establishing the activation of TCN-P by ADK
led to its inclusion in the NCI’s standard anticancer agent
database.
According to Michaelis-Menten kinetics, the rate of drug
activation—and consequently, growth inhibitory activity—
should be proportional to the relative amounts of activating
enzyme concentration, for a set intracellular substrate con-
centration. To better analyze the within-tissue type associa-
tion, the correlation between ADK expression and TCN-P
cell growth inhibitory activity was calculated independently
for each tumor tissue type, and compared to that of other
gene:drug associations. Based on this analysis, ADK expres-
sion exhibits a strong negative correlation with the concen-
tration of TCN-P needed to inhibit cell growth (Fig. 3). This
finding indicates that ADK expression can be predictive of
chemosensitivity across and within tumor tissues, as expected
from a true mechanistic relationship between ADK expres-
sion and TCN-P activation.
By calculating the average within tumor correlation
across the eight different tumor tissues analyzed and plotting
it against the overall correlation, the strength of TCN-P:ADK
association can also be compared to the other gene:drug pairs
examined. This analysis underscores the strength of the TCN-
P:ADK correlation, relative to those of other clinically-
relevant drugs with known intracellular targets (Fig. 4). Over-
all, the within-tissue correlations are slightly stronger than the
across tumor tissue correlations. This suggests that the rela-
tionship is not due to the confounding effects of tissue specific
gene expression or tissue specific chemosensitivity. Moreover,
the within tissue correlations for TCN-P:ADK are consis-
tently negative (17/18 of the correlations are negative in the
two replications). Both of these observations are consistent
with the hypothesis that enzymatic activation of TCN-P by
ADK in cancer cells is a common and specific phenomenon,
across and within tissue types.
In addition to TCN-P:ADK, there are two other outliers
in the overall vs. within-tumor correlation plot (Fig. 4). One
of them (0.63, 0.05) is for ara-6-mp/RNA polymerase II. This
is just one of 14 probes of RNA polymerase II on the array,
however, and the other 13 do not show correlation. The other
outlier (0.31, 0.5) is for rhizoxin/beta-tubulin, but again there
are many beta tubulin probes on the array and only one shows
correlation. Although these apparent associations may be ex-
perimental noise, it is possible that the expression of a specific
tubulin or polymerase II isoform may determine the activity
Fig. 2. Triciribine phosphate (TCN-P) is de-phosphorylated extracel-
lularly, traverses the plasma membrane, and is activated by intracel-
lular re-phosphorylation catalyzed by ADK.
Fig. 3. Within-tumor Pearson correlations between the NCI’s standard anticancer drug set and genes
associated with drug mechanism of action. A total of 364 drug/gene pairs were considered, based on
experimental evidence for mechanistic drug-gene association found in the scientific literature. The solid
lines connect the correlations between TCN-P and two probes for ADK. The tumor types are: B: breast;
G: lung; C: CNS; L: leukemia; M: melanoma; N: colon; O: ovarian; R: renal. Prostate was excluded from
this analysis, as there are only two cell lines in the prostate panel.
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of rhizoxin or ara-6-mp respectively, and we are exploring the
nature of this association in greater detail. Nevertheless, the
strength of the TCN-P:ADK correlation, occurring in two
replications across and within tumor tissues, far surpasses that
of all other gene:drug pairs.
To establish whether the TCN-P:ADK association is
likely to reproduce, we considered several sources of experi-
ment error that may produce false positives when carrying out
correlation analysis in a large dataset. To test whether the
observed TCN-P:ADK correlation may be caused by random
chance, a statistical simulation was carried out as described in
the Methods (results shown in the supplementary table). For
both copies of ADK on the array, the overall correlation is
significant (p < 0.001). In addition, we considered whether the
strongest of the 364 associations in a simulated dataset (as
opposed to the simulated association for TCN-P:ADK in par-
ticular) is stronger than the observed TCN-P:ADK correla-
tion. Again, in this case, the p values are small and significant
for both copies of ADK (p < 0.01). Within each tumor tissue
the TCN-P:ADK association is significant for both copies of
ADK (p < 0.01 for TCN-P:ADK in particular; p < 0.05 for the
maximum within group correlation over all 364 pairs studied).
Finally, to combine the evidence contained in the overall- and
within-tumor correlations, we considered the probability that
a gene:drug pair would have stronger within-tumor and over-
all correlations than the observed values for TCN-P:ADK.
Using the statistical simulation analysis described in the
Methods, this was found to be unlikely for both copies of
ADK (p < 0.001 for the TCN-P:ADK association in particu-
lar; p < 0.01 for all 364 gene:drug pairs simultaneously).
DISCUSSION
In pursuit of personalized anticancer treatments, gene-
drug associations directly relevant to drug mechanism of ac-
tion would be useful for tailoring anticancer therapy to the
phenotypic characteristics of cancer cells. We have found that
ADK gene expression levels, as determined with oligonucleo-
tide microarrays, are predictive of the response of cells to
TCN-P across a panel of 60 cell lines derived from different
tumor tissues. This result is consistent with the requirement of
intracellular ADK for activating TCN-P. It supports the no-
tion that catalytic drug activation can be used to personalize
anticancer therapy, by monitoring the expression level of
drug activating enzymes.
As a mechanistic hypothesis, the predictive power be-
hind the TCN-P:ADK association resides in the inactivity of
the drug in cells that do not express ADK, together with the
enzyme-catalyzed intracellular accumulation of the mem-
brane impermeant, activated drug in cells expressing ADK.
As a corollary, we predict that our observations are not
unique to the TCN-P:ADK association or to phosphorylation
reactions and that other enzymatic activation mechanisms
could be exploited for similar purposes. For example, ester
hydrolysis yields a cell-impermeable carboxylate product. An
inactive, cell-permeable ester prodrug could be rationally de-
signed as a substrate for an esterase, such that accumulation
of an active carboxylate drug product should be proportional
to esterase expression.
Is the discovered correlation between TCN-P and ADK
real? Statistically, we have considered the possibility that the
association may be a false positive, because of a random ex-
Fig. 4. Bivariate plots of mechanistically relevant gene-drug activity correlations, across and within
tumor tissue types in the 60-cell line panel. (T: TCN-P correlated with two ADK probes; P: paclitaxel
correlated with multiple - and -tubulin probes; D: doxorubicin correlated with multiple topoisomerase
II probes; H: hydroxyurea correlated with a ribonucleotide reductase probe; M: methotrexate correlated
with multiple dihydrofolate reductase probes. The “+” symbols indicate identified correlations for the
other drugs in the database.
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perimental variation producing a spurious association. We
calculate that this is unlikely, with a probability <0.001 that
both within-tumor and overall correlations as strong as those
observed for TCN-P:ADK could be found by chance. This
result was reproduced simultaneously for two independent
measurements of ADK expression, making it even less likely
to be due to chance variation. Moreover -in the particular
case of TCN-P:ADK correlation- chemical, biochemical, and
pharmacological experiments support the notion that ADK
gene expression is mechanistically and causally related to the
level of TCN-P activity (9,11–13).
In conclusion, the catalytic drug activation mechanism
exemplified by the ADK:TCN-P association may provide a
rational approach to the development of personalized thera-
pies. For all mechanistically-relevant gene:drug associations
explored in the NCI standard anticancer agent database, the
use of ADK expression for stratifying TCN-P responsive vs.
non-responsive tumors presents the most promising gene:
drug relationship with potential application to personalized
therapy. These results are consistent with the fact that TCN-P
is inactive unless activated by adenosine kinase, and that the
level of adenosine kinase expression determines the activity
of TCN-P against different tumor cells. In preliminary phase
I and II clinical trials, TCN-P is tolerated (14,15). Based on
the rational, mechanistic hypothesis supported by the results
presented here, we propose that TCN-P be reconsidered as an
advanced, experimental drug candidate for personalized
therapy against ADK-over-expressing tumors.
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